Home » Stocks » XBIT

XBiotech Inc. (XBIT)

Stock Price: $19.11 USD 0.17 (0.90%)
Updated Feb 26, 2021 3:56 PM EST - Market closed
After-hours: $19.00 -0.11 (-0.58%) Feb 26, 5:22 PM
Market Cap 556.10M
Revenue (ttm) 38.73M
Net Income (ttm) 677.11M
Shares Out 29.04M
EPS (ttm) 16.45
PE Ratio 1.16
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $19.11
Previous Close $18.94
Change ($) 0.17
Change (%) 0.90%
Day's Open 19.17
Day's Range 18.58 - 19.52
Day's Volume 116,902
52-Week Range 8.72 - 21.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectiou...

GlobeNewsWire - 1 month ago

Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Member...

Investopedia - 2 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: ATEN, EYE, FCEL, NVAX, SWBI, UIS, VHC, VXRT
Investopedia - 2 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

Other stocks mentioned: CTRN, LPX, NLS, NVAX, UCTT, UIS, VHC, VXRT
Seeking Alpha - 3 months ago

XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4...

GlobeNewsWire - 3 months ago

Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential

Investopedia - 3 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.

Other stocks mentioned: BIG, CODX, NVAX, TGH, TTMI, UIS, VHC, VXRT
GuruFocus - 3 months ago

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBI...

Other stocks mentioned: CPRX, PRDO, SBR, VNDA
Investopedia - 4 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIG, CODX, NVAX, TGH, TTMI, UIS, VHC, VXRT
GlobeNewsWire - 5 months ago

With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a ...

Investopedia - 5 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, MRSN, NVAX, REGN, TECH, VNDA
Investopedia - 5 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for September.

Other stocks mentioned: CODX, ICHR, NVAX, PRTS, TGH, TTM, UIS, VHC
GlobeNewsWire - 6 months ago

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients

24/7 Wall Street - 6 months ago

XBiotech Inc. (NASDAQ: XBIT) shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.

GlobeNewsWire - 6 months ago

The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immun...

InvestorPlace - 6 months ago

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

Other stocks mentioned: ALXN, CRSP, EDIT, VRTX
Seeking Alpha - 6 months ago

XBiotech: Well Funded, Working On The Next Bermekimab, And Undervalued

GlobeNewsWire - 7 months ago

After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021 After Sale of its Previous Anti-IL...

InvestorPlace - 7 months ago

When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.

Other stocks mentioned: ARLO, ITRN, LQDA, RADA, SWIR, VERI
GlobeNewsWire - 7 months ago

Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy Antibody Therapy Targeting Interleukin-1a...

Investopedia - 8 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, TRIL, VNDA, VRTX
GlobeNewsWire - 9 months ago

Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19

Investopedia - 9 months ago

These are the small cap stocks with the best value, fastest growth, and most momentum for May.

Other stocks mentioned: KOD, TPH
InvestorPlace - 9 months ago

These exciting stocks to buy for aggressive investors might be small, but they have massive growth potential when the pandemic clears up. The post 7 Top Stocks to Buy for Aggressive Investor...

Other stocks mentioned: DRD, ENPH, IFMK, NH, OESX
GlobeNewsWire - 10 months ago

New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021 New antibody to block IL-1⍺ scheduled to enter clinical trials as next gener...

GlobeNewsWire - 10 months ago

AUSTIN, Texas, April 03, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration ...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor.  The co...

The Motley Fool - 1 year ago

The company's offer to buy back shares was overtendered, resulting in a prorated deal.

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired...

Seeking Alpha - 1 year ago

XBiotech Is Trading Below Its $30 Offer Price For Good Reason, But It Still Could Rise

The Motley Fool - 1 year ago

The company is offering to buy back shares from investors at a big premium.

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,00...

GlobeNewsWire - 1 year ago

Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-...

Seeking Alpha - 1 year ago

XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The a...

The Motley Fool - 1 year ago

XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.

24/7 Wall Street - 1 year ago

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.

Other stocks mentioned: ARQL, THO
GlobeNewsWire - 1 year ago

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen X...

GlobeNewsWire - 1 year ago

Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Berme...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evalu...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Oct. 23, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 ...

GlobeNewsWire - 1 year ago

Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a...

GlobeNewsWire - 1 year ago

Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019 Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Satur...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) cove...

InvestorPlace - 1 year ago

Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?

Other stocks mentioned: AGN, CRSP, REGN, VRTX

About XBIT

XBiotech, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Diffici... [Read more...]

Industry
Biotechnology
IPO Date
Apr 15, 2015
CEO
John Simard
Employees
89
Stock Exchange
NASDAQ
Ticker Symbol
XBIT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for XBiotech is 18.00, which is a decrease of -5.81% from the latest price.

Price Target
$18.00
(-5.81% downside)